INDEX 839
low-dose dexamethasone suppression test
(LDDST), 398, 403, 411
Loxosceles reclusa(brown recluse spider), 240, 242
Loxosceles unicolor(common brown spider), 240, 242
lufenuron, 325, 787
lufenuron + milbemycin oxime, 787
Luminalseephenobarbital
lung-digit syndrome,136, 600, 688
lupoid onychitis, symmetric, 589
lupoid onychodystrophy, symmetric,133,589, 594,
596–597, 604
lupus erythematosus (LE), 467–472
cutaneousseecutaneous lupus erythematosus
discoidseediscoid lupus erythematosus
keratinization disorder, 435, 456
systemicseesystemic lupus erythematosus
lymphocytosis, cutaneous
clinical features, 618, 619, 626
diagnostics, 622
differential diagnosis, 620, 621
etiology/pathophysiology, 615, 616
signalment/history, 617
therapeutics, 623, 625
lymphomaseecutaneous nonepitheliotropic
lymphoma; epitheliotropic lymphoma
lymphomatoid granulomatosis, 383
lymphosarcoma, 565, 604
L-lysine, 715, 788
Lysodrenseemitotane
MAB IBF9 antigen, 673
Macrodantinseenitrofurantoin
macromelanosome, 44, 52
macronychia, 588
macular melanosis, 65
macules
bacterial pyoderma, 215, 226
defined, 13, 17
magnetic resonance imaging (MRI)
for deep mycoses, 523
for hyperadrenocorticism, 397, 411
for otitis, 546
malamute, 417, 674
see alsoAlaskan malamute
Malasseziadermatitis, 480–484
adverse food reactions, 287, 291
atopic disease, 182,183, 184
clinical features, 481,486–492
diagnostics, 46, 47,53–54,482–483,492–493
differential diagnosis, 177, 482
facts for pet owners, 484, 485
keratinization disorders, 432, 433,444, 445, 448
paronychia, 589, 601
signalment/history, 481
therapeutics, 438, 483–484
Malassezia pachydermatis, 480, 484
malignant fibrous histiocytoma, 381, 383, 385, 387
malnutrition, 435, 456
Malogenseetestosterone
Maltese, 699, 739
Manchester terrier, 60, 432, 739
marbofloxacin, 788
for mycobacterial infections, 515
for otitis, 550
for pyoderma, 219
Marcaineseebupivacaine hydrochloride
Marinseesilymarin
maropitant, 788
mast cell tumors, 494–500
canine grading systems, 497
clinical features, 495–496,500–509
course and prognosis, 499–500
diagnostics, 496–497, 509
differential diagnosis, 496, 565
signalment/history, 494–495
therapeutics, 497–499
mastiff, 157, 214, 739
masitinib, 499
mastocytosis, cutaneous, 615, 617
clinical features,508, 618
diagnostics, 622
differential diagnosis, 620
therapeutics, 623
Maxolonseemetoclopramide
mecA gene, 143
mechlorethamine, 369
meclizine, 789
Meclofenseemeclofenamate
meclofenamate, 789
medetomidine, 789
Medrolseemethylprednisolone
medroxyprogesterone acetate, 341, 789
Mefoxinseecefoxitin sodium
megestrol acetate, 790
adverse effects, 339,349, 364, 414
for eosinophilic granuloma complex, 355
meglumine antimoniate, 463
melanin granules, 48
melanocytic tumors, 672–673
clinical features, 676,683–684
diagnostics, 677, 678
differential diagnosis, 677
malignantseemelanoma, malignant
prognosis, 679
signalment/history, 673, 674, 675
therapeutics, 678–679
melanoderma/alopecia of Yorkshire terriers, 60, 65
melanoma, malignant
client education, 679
clinical features, 66,131, 614,676, 684
etiology/pathophysiology, 672–673
melanosis, 40
melatonin, for alopecia X, 341
meloxicam, 790
mepivacaine, 791
6-mercaptopurine, 791